T. N. Yunasova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
T. N. Yunasova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Artashes A. Movsesyants
Scientific Centre for Expert Evaluation of Medicinal Products
5 shared publications - A. S. Binyatova
Scientific Centre for Expert Evaluation of Medicinal Products
4 shared publications - Karine A. Sarkisyan
Scientific Centre for Expert Evaluation of Medicinal Products
4 shared publications - T. N. Ilyasova
Scientific Centre for Expert Evaluation of Medicinal Products
4 shared publications - Vadim Anatolievich Merkulov
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications - Рауза Асхатовна Волкова
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications
Latest Publications
- Open Access
- 21 September 2023
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 68 (4) , 327-333
Experience with the use of pharmacopoeial reference material for the activity of measles vaccine
Introduction. Due to the increased incidence of measles in Russia and in many other regions of the world, vaccines for the measles prevention are especially in demand. Ensuring the quality of the measles vaccine for effective disease prevention is within the scope of the tasks of the state policy of our country. Objective. Evaluation of the experience of using a pharmacopoeial standard material of measles vaccine activity for measurement of the specific activity of the measles virus in vaccines with a measles component that are used in the Russian Federation for measles prevention. Materials and methods. The object of the study was the Pharmacopoeia reference material (PRM) of the activity of the live measles vaccine of series 10. The activity of PRM was analyzed when determining the specific activity of the measles, mumps-measles and combined vaccines for the prevention of measles, rubella and mumps, as well as based on the materials of the summary protocols for the production of these vaccines. Results. The titer of the measles virus in the PRM for each determination of the specific activity of the measles virus in vaccines in the Scientific Centre for Expert Evaluation of Medicinal Products in 20212022, as well as according to the summary production protocols, was within the boundaries of the certified value (4.63 0.5) lgTCD50/0.5 ml, and the test results met the acceptance criteria in accordance with the requirements of regulatory documentation. During the observation period, the average value of the PRM titer (4.61 lgTCD50/0.5 ml) practically did not differ compared to the average value of the certified characteristics of the PRM, the standard deviation of the mean value of the measles virus titer in the PRM did not exceed 0.15 lgTCD50, which indicated the stability of the analytical work at the enterprise and in IC. Conclusion. The data obtained indicate the stable activity of PRM, the correctness of the determination of the measles virus titer in the vaccination dose of the vaccine, and the validity of the method for monitoring the specific activity of the measles virus in vaccines.
- 21 September 2023
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 68 (4) , 327-333
Open AccessExperience with the use of pharmacopoeial reference material for the activity of measles vaccine
Introduction. Due to the increased incidence of measles in Russia and in many other regions of the world, vaccines for the measles prevention are especially in demand. Ensuring the quality of the measles vaccine for effective disease prevention is within the scope of the tasks of the state policy of our country. Objective. Evaluation of the experience of using a pharmacopoeial standard material of measles vaccine activity for measurement of the specific activity of the measles virus in vaccines with a measles component that are used in the Russian Federation for measles prevention. Materials and methods. The object of the study was the Pharmacopoeia reference material (PRM) of the activity of the live measles vaccine of series 10. The activity of PRM was analyzed when determining the specific activity of the measles, mumps-measles and combined vaccines for the prevention of measles, rubella and mumps, as well as based on the materials of the summary protocols for the production of these vaccines. Results. The titer of the measles virus in the PRM for each determination of the specific activity of the measles virus in vaccines in the Scientific Centre for Expert Evaluation of Medicinal Products in 20212022, as well as according to the summary production protocols, was within the boundaries of the certified value (4.63 0.5) lgTCD50/0.5 ml, and the test results met the acceptance criteria in accordance with the requirements of regulatory documentation. During the observation period, the average value of the PRM titer (4.61 lgTCD50/0.5 ml) practically did not differ compared to the average value of the certified characteristics of the PRM, the standard deviation of the mean value of the measles virus titer in the PRM did not exceed 0.15 lgTCD50, which indicated the stability of the analytical work at the enterprise and in IC. Conclusion. The data obtained indicate the stable activity of PRM, the correctness of the determination of the measles virus titer in the vaccination dose of the vaccine, and the validity of the method for monitoring the specific activity of the measles virus in vaccines.
- Open Access
- 19 November 2022
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 67 (5) , 414-422
Quality analysis of a combined domestic vaccine for the prevention of measles, rubella and mumps
Introduction. The need to maintain a high level of vaccination coverage against measles, rubella and mumps in conditions of an increased risk of outbreaks of infections due to violations of vaccination tactics associated with the pandemic of coronavirus infection and due to the unfavorable epidemic situation in neighboring countries determines the advisability of using a combined vaccine for the simultaneous prevention of these three socially significant infections. The aim of the study: to analyze the quality of commercial series of a new domestic combined cultured live vaccine against measles, rubella and mumps (MRM) throughout the entire time of its manufacturing according to all specification indicators in regulatory documentation (RD). Materials and methods. The object of the study was the combined cultured live vaccine against measles, rubella and mumps. The analysis of the quality of the drug was carried out according to 86 consolidated production protocols of manufactured series, as well as according to the results of control of these series in the Testing Center for Quality Expertise of the Federal State Budgetary Institution NCESMP of the Ministry of Health of the Russian Federation. Results. It is shown that the quality of the combined drug for the prevention of measles, rubella and mumps corresponds to the RD in all studied indicators. The drug does not contain an antibiotic. Bovine serum albumin, which is a technological impurity, is detected in quantities more than 5 times lower than the established norm. A comparison of the specific activity of the viral components of new combined domestic vaccine and the components of the bivalent vaccine against measles and mumps produced by the company in 20192021 showed that the spread of the activity values of the viral components in the new drug and in the series of mumps-measles vaccine was minimal, which allowed us to make a conclusion about the stability of the production technology. Conclusion. The quality of the new domestic combined vaccine for the prevention of measles, rubella and mumps meets WHO requirements. The results of the conducted studies indicate the stability of production and the standard quality of the drug. The use of a combined vaccine against three significant infections will ensure the necessary level of vaccination coverage in the population. Information about the results of studies can help reduce the number of vaccination refusal.
- 19 November 2022
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 67 (5) , 414-422
Open AccessQuality analysis of a combined domestic vaccine for the prevention of measles, rubella and mumps
Introduction. The need to maintain a high level of vaccination coverage against measles, rubella and mumps in conditions of an increased risk of outbreaks of infections due to violations of vaccination tactics associated with the pandemic of coronavirus infection and due to the unfavorable epidemic situation in neighboring countries determines the advisability of using a combined vaccine for the simultaneous prevention of these three socially significant infections. The aim of the study: to analyze the quality of commercial series of a new domestic combined cultured live vaccine against measles, rubella and mumps (MRM) throughout the entire time of its manufacturing according to all specification indicators in regulatory documentation (RD). Materials and methods. The object of the study was the combined cultured live vaccine against measles, rubella and mumps. The analysis of the quality of the drug was carried out according to 86 consolidated production protocols of manufactured series, as well as according to the results of control of these series in the Testing Center for Quality Expertise of the Federal State Budgetary Institution NCESMP of the Ministry of Health of the Russian Federation. Results. It is shown that the quality of the combined drug for the prevention of measles, rubella and mumps corresponds to the RD in all studied indicators. The drug does not contain an antibiotic. Bovine serum albumin, which is a technological impurity, is detected in quantities more than 5 times lower than the established norm. A comparison of the specific activity of the viral components of new combined domestic vaccine and the components of the bivalent vaccine against measles and mumps produced by the company in 20192021 showed that the spread of the activity values of the viral components in the new drug and in the series of mumps-measles vaccine was minimal, which allowed us to make a conclusion about the stability of the production technology. Conclusion. The quality of the new domestic combined vaccine for the prevention of measles, rubella and mumps meets WHO requirements. The results of the conducted studies indicate the stability of production and the standard quality of the drug. The use of a combined vaccine against three significant infections will ensure the necessary level of vaccination coverage in the population. Information about the results of studies can help reduce the number of vaccination refusal.
- Open Access
- 3 May 2021
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 20 (2) , 58-67
Monitoring the quality of domestic measles prevention vaccines
Relevance. The need to increase vaccination coverage in order to eliminate measles in Russia and increase public confidence in vaccination requires constant monitoring of the quality of vaccines used for measles prevention. Aim. Analysis of laboratory quality parameters of commercial series of vaccines for measles prevention produced by JSC NPO Microgen, issued from 2015 to 2020, in comparison with the series issued in the period from 2002 to 2009. Materials and methods. The object of the study was a live measles culture vaccine and a live mumps-measles culture vaccine produced by JSC «NPO «Microgen». The quality analysis of vaccines was carried out according to the consolidated production and control protocols of 422 series of measles vaccine and 855 series of mumps-measles vaccine issued in 2015-2020, and 1043 series of measles vaccine and 902 series of mumpsmeasles vaccine issued in 2002-2009. Results and discussion. It is shown that the quality of the studied vaccines is stable during 16 years of monitoring. The sensitizing properties of both vaccines significantly decreased during the last 6 years of follow-up due to a decrease in the residual content of the antibiotic in the vaccination dose to less than the detection limit, as well as due to the low content of heterogeneous protein (bovine serum albumin). Conclusion. The quality of domestic vaccines for the prevention of measles and mumps meets who requirements; it is characterized by stability over 16 years of follow-up and minimal sensitizing properties. Information about the quality of domestic vaccines for the prevention of measles is an important argument for countering the antivaccination movement, which is a global problem and is recognized by who as one of the most important threats to the health of the world's population.
- 3 May 2021
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 20 (2) , 58-67
Open AccessMonitoring the quality of domestic measles prevention vaccines
Relevance. The need to increase vaccination coverage in order to eliminate measles in Russia and increase public confidence in vaccination requires constant monitoring of the quality of vaccines used for measles prevention. Aim. Analysis of laboratory quality parameters of commercial series of vaccines for measles prevention produced by JSC NPO Microgen, issued from 2015 to 2020, in comparison with the series issued in the period from 2002 to 2009. Materials and methods. The object of the study was a live measles culture vaccine and a live mumps-measles culture vaccine produced by JSC «NPO «Microgen». The quality analysis of vaccines was carried out according to the consolidated production and control protocols of 422 series of measles vaccine and 855 series of mumps-measles vaccine issued in 2015-2020, and 1043 series of measles vaccine and 902 series of mumpsmeasles vaccine issued in 2002-2009. Results and discussion. It is shown that the quality of the studied vaccines is stable during 16 years of monitoring. The sensitizing properties of both vaccines significantly decreased during the last 6 years of follow-up due to a decrease in the residual content of the antibiotic in the vaccination dose to less than the detection limit, as well as due to the low content of heterogeneous protein (bovine serum albumin). Conclusion. The quality of domestic vaccines for the prevention of measles and mumps meets who requirements; it is characterized by stability over 16 years of follow-up and minimal sensitizing properties. Information about the quality of domestic vaccines for the prevention of measles is an important argument for countering the antivaccination movement, which is a global problem and is recognized by who as one of the most important threats to the health of the world's population.
- Open Access
- 17 September 2019
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 19 (3) , 154-160
Analysis of Measles Incidence in Russia and Problems of Measles Prevention at the Elimination Stage
The review analyses measles incidence in Russia at the elimination stage. Epidemiological studies have revealed changes in the measles epidemic process in Russia. It was shown that whereas the specificity of the epidemic process in the pre-vaccination period was mainly determined by the influence of the infectious agent, lately the impact of the social factor has increased. There was an increase in the impact of decreed groups on maintaining the circulation of the virus in the Russian Federation. The aim of the study was to analyse the specificity of the measles epidemic process in Russia, to identify the major current problems of measles vaccination, to reveal reasons that prevent measles elimination in the country given the present environment, and to formulate possible ways of solving them. The article demonstrates the role of migration processes within the country and infection importation from neighboring territories in the rise of disease outbreaks. The article discusses Russian regulatory documents that are devoted to combating the spread of measles, their consistent replacement and refinement bearing in mind the changing epidemiological situation and the current WHO criteria and guidelines for the infection elimination. High-level epidemiological surveillance of the infection is a key factor in choosing the optimal strategy of measles vaccination. The article lists indicators of epidemiological surveillance effectiveness. It also highlights the importance of molecular genetic monitoring of the measles pathogen. The authors outline measures that are necessary to achieve measles elimination in the Russian Federation given the current epidemiological situation.
- 17 September 2019
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 19 (3) , 154-160
Open AccessAnalysis of Measles Incidence in Russia and Problems of Measles Prevention at the Elimination Stage
The review analyses measles incidence in Russia at the elimination stage. Epidemiological studies have revealed changes in the measles epidemic process in Russia. It was shown that whereas the specificity of the epidemic process in the pre-vaccination period was mainly determined by the influence of the infectious agent, lately the impact of the social factor has increased. There was an increase in the impact of decreed groups on maintaining the circulation of the virus in the Russian Federation. The aim of the study was to analyse the specificity of the measles epidemic process in Russia, to identify the major current problems of measles vaccination, to reveal reasons that prevent measles elimination in the country given the present environment, and to formulate possible ways of solving them. The article demonstrates the role of migration processes within the country and infection importation from neighboring territories in the rise of disease outbreaks. The article discusses Russian regulatory documents that are devoted to combating the spread of measles, their consistent replacement and refinement bearing in mind the changing epidemiological situation and the current WHO criteria and guidelines for the infection elimination. High-level epidemiological surveillance of the infection is a key factor in choosing the optimal strategy of measles vaccination. The article lists indicators of epidemiological surveillance effectiveness. It also highlights the importance of molecular genetic monitoring of the measles pathogen. The authors outline measures that are necessary to achieve measles elimination in the Russian Federation given the current epidemiological situation.
- Open Access
- 20 December 2018
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 18 (4) , 249-256
Using Real-Time RT-PCR Reagent Kits for Identity Testing of Measles, Mumps and Rubella Vaccines
Currently, the identity of measles, mumps and rubella virus vaccines is determined during certification testing by a labour-consuming, lengthy and costly neutralisation test using cell cultures. The identity of the virus contained in such vaccines is established based on neutralisation of cytopathic effect of viruses in sensitive RK-13 and Vero cell cultures using a specific immune serum. An urgent challenge is to simplify and reduce the cost of controlling the identity of commercial batches of measles, mumps and rubella vaccines using polymerase chain reaction (PCR) tests. The aim of the study was to determine the possibility of viral ribonucleic acid (RNA) detection in these vaccines using reagent kits from different manufacturers for detection of measles, mumps and rubella viruses in clinical material by real-time reverse transcription-PCR (RT-PCR). The article presents the results of the study, which assessed the possibility of using the real-time RT-PCR for testing the identity of measles, mumps and rubella viruses in vaccines. The authors of the study analysed domestically produced and foreign reagent kits intended for detection of measles, mumps and rubella viruses in clinical material. All the studied reagent kits were able to detect RNAs of the above-mentioned viruses in vaccine products. All the reagent kits demonstrated high specificity and could be used to confirm the identity of the measles, mumps and rubella viruses in all the studied vaccines. Commercial domestic reagent kits can be used to determine the identity of rubella vaccines by RT-PCR. However, it is advisable to develop domestic reagent kits for checking the identity of measles and mumps vaccines by RT-PCR. The acceptability of the test results was assessed using the industry reference standards of measles, mumps and rubella viruses activity with certified stable activity values.
- 20 December 2018
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 18 (4) , 249-256
Open AccessUsing Real-Time RT-PCR Reagent Kits for Identity Testing of Measles, Mumps and Rubella Vaccines
Currently, the identity of measles, mumps and rubella virus vaccines is determined during certification testing by a labour-consuming, lengthy and costly neutralisation test using cell cultures. The identity of the virus contained in such vaccines is established based on neutralisation of cytopathic effect of viruses in sensitive RK-13 and Vero cell cultures using a specific immune serum. An urgent challenge is to simplify and reduce the cost of controlling the identity of commercial batches of measles, mumps and rubella vaccines using polymerase chain reaction (PCR) tests. The aim of the study was to determine the possibility of viral ribonucleic acid (RNA) detection in these vaccines using reagent kits from different manufacturers for detection of measles, mumps and rubella viruses in clinical material by real-time reverse transcription-PCR (RT-PCR). The article presents the results of the study, which assessed the possibility of using the real-time RT-PCR for testing the identity of measles, mumps and rubella viruses in vaccines. The authors of the study analysed domestically produced and foreign reagent kits intended for detection of measles, mumps and rubella viruses in clinical material. All the studied reagent kits were able to detect RNAs of the above-mentioned viruses in vaccine products. All the reagent kits demonstrated high specificity and could be used to confirm the identity of the measles, mumps and rubella viruses in all the studied vaccines. Commercial domestic reagent kits can be used to determine the identity of rubella vaccines by RT-PCR. However, it is advisable to develop domestic reagent kits for checking the identity of measles and mumps vaccines by RT-PCR. The acceptability of the test results was assessed using the industry reference standards of measles, mumps and rubella viruses activity with certified stable activity values.